This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
FPR2 Agonist Program (Kyorin)
Bristol-Myers Squibb Company
Description: A formyl peptide receptor (FPR) agonist is being developed. FPR-2 agonists mainly inhibit the migration of neutrophils and exhibit anti-inflammatory action.
Kyorin and Bristol-Myers Squibb
In December 2015, KYORIN Pharmaceutical announced a license agreement with Bristol-Myers Squibb for Kyorin Pharmaceuticals FPR2 agonist program. Under the terms of the agreement, Kyorin Pharmaceutical grants Bristol-Myers Squibb exclusive worldwide license to develop, manufacture and commercialize products within the program and in return, Bristol-Myers Squibb will make an upfront payment of US$35 million. Kyorin Pharmaceutical will be also eligible to receive up to US$370 million in development and regulatory milestones, along with royalties on net sales and sales based milestones. Kyorin Pharmaceutical will have an option to collaborate with Bristol-Myers Squibb in the development and commercialization in Japan.
Partners: Kyorin Pharmaceutical Co., Ltd.
FPR2 Agonist Program (Kyorin) News
Additional information available to subscribers only: